Oncology Services to Advance Research

Get expert support for your oncology drug discovery program with our comprehensive preclinical solutions.

Leverage our experience to accelerate your oncology discovery programs.

  • Choose from a broad range of tumor lines, spanning both human and murine cell lines.

  • Support your immunotherapy development programs with well characterized syngeneic models.

  • Work with a trusted CRO partner in drug development – from lead optimization to IND and into the clinic.

A specimen under a microscope during a clinical oncology study.
Your Needs

A broad range of models

Get the preclinical testing support you need with our in vivo oncology solutions. We can support small molecules, biologics and cell-based therapies to advance your program.

Services include the development of test articles for monotherapy, immunotherapy and combination therapies. Our efficacy evaluation can also be combined with PK/PD, hematology, histopathology, biomarker screening and immunophenotyping.

Rely on our scientific expertise and get advice on the most appropriate model system for evaluating your cancer therapy.


Human tumor lines

Models with Profile

Disease (Histotype)

Cell Lines

Bladder

UM-UC-3

Brain

U-87-MG

Breast

BT-474, MCF7, MDA-MB-231

Colon

Colo-205, HCT-116, HCT-15, HT-29, SW48, SW1463

Head and Neck

A-253, KYSE-150, KYSE-30, Detroit 562

Gastric/Stomach

MKN-45, NCI-N87, GIST-T1

Kidney

786-O

Leukemia

HL-60, MOLM-13, MV-4-11

Lung

A549, Calu-6, DMS-273, HCC827, HCT-15, NCI-H1975, NCI-H2122, NCI-H460, Calu-3, NCI-H441, Calu-1, NCI-H2030, NCI-H1373, NCI-H1155, NCI-H358, NCI-H292

Lymphoma

Raji, Daudi, U-937, JeKo-1

Melanoma

A2058, A375

Myeloma

RPMI-8226, OPM-2, MOLP-8

Ovary

A2780, OVCAR-3, SK-OV-3

Pancreas

AsPC-1, BxPC-3, MIA-PaCA-2, PANC-1, Capan-1, PA-TU-8988T

Prostate

LNCaP, PC-3, 22Rv1

Sarcoma

HT-1080, SJSA-1

 

Models without Profile

Disease (Histotype)

Cell Lines

Bladder

RT-112, RT4, SW780, T-24,

Brain

LN-229, IMR-32, T98G, BT142

Breast

T47D, MDA-MB-453, MDA-MB-361, JIMT-1, HCC38

Colon

DLD-1, SW480, SW620, HCT-15

Head and Neck

KYSE-510, SCC-4, OE19

Gastric/Stomach

Hs746T, Katolll, SNU1, SNU16,

Leukemia

KU812, KU812F, MOLT-4, HEL 92.1.7*, K-562, RS4(11), DEL, JJN-3, L363, MOLM-16

Lung

NCI-H1155, NCI-H358, NCI-H520, NCI-H23,HCC-44, NCI-H727, NCI-H1299, NCI-H1650, NCI-H446

Lymphoma

DOHH-2, WSU-NHL, WSU-DLCL2

Melanoma

HMCB, WM-115, SK-MEL-3

Myeloma

U266B1

Ovary

EFO-21

Pancreas

Capan-2

Sarcoma

Saos-2

 


Syngeneic (murine) tumor lines

Disease (Histotype)

Cell Line

Breast

4T1, EMT6

Colon

CT26-WT, MC-38

Kidney

RENCA

Liver

Hepa129

Lung

LL/2

Lymphoma

A20

Melanoma

B16-F10

 


Humanized mouse models

We offer humanized mouse models (hCD34+ or fresh hPBMC engraftment). Specific models and assays can be developed per your request. Please contact us to receive a complete list or discuss your current needs.

Innovative imaging technologies

Take advantage of several options for in vivo visualizations of your therapy’s effect. We can guide your decision-making process to evaluate the best approach and show how these valuable data can answer key questions about your therapy and help translate results to the clinic.

  • IVIS non-invasive bioluminescent imaging
  • CT imaging
    • Tumor assessment with readouts of bone destruction
    • Angiogenesis using contrast agents
    • Renal tumor measurements using contrast agents

Insights for oncology in vitro assays

Our Translational Biomarker Solutions group is fully equipped to support your needs for oncology in vitro assays.

  • Target and pathway activity modulation
  • Agonist and antagonist reporter assays
  • Biochemical assays and immunoassays to evaluate target expression, engagement and modulation
  • Cellular toxicity and proliferation assays
  • Cell death assays including apoptosis assays
  • Angiogenesis and cell migration assays
  • ADCC and CDC activity assays
  • Phenotypic and functional characterization of various cell types using flow cytometry
  • Cell-based biomarker discovery and qualification
  • Immunological assessment of therapeutic article or vaccine efficacy

Let us help you guide your strategy and reach crucial decision points in your development. Together, we can design a solution that meets your unique needs and work to accelerate your oncology program.